{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:37Z","timestamp":1790757697345,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00520-018-4618-y","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:28:17Z","timestamp":1546561697000},"page":"3053-3059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies"],"prefix":"10.1007","volume":"27","author":[{"given":"Julien","family":"Rossignol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Liebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel-Louis","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"issue":"14","key":"4618_CR1","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/S0959-8049(02)00229-0","volume":"38","author":"G Cavaletti","year":"2002","unstructured":"Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38(14):1832\u20131837","journal-title":"Eur J Cancer"},{"issue":"3","key":"4618_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/157015906778019536","volume":"4","author":"P Marchettini","year":"2006","unstructured":"Marchettini P, Lacerenza M, Mauri E, Marangoni C (2006) Painful peripheral neuropathies. Curr Neuropharmacol 4(3):175\u2013181","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"4618_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14737140.2017.1374856","volume":"17","author":"M Bakogeorgos","year":"2017","unstructured":"Bakogeorgos M, Georgoulias V (2017) Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Expert Rev Anticancer Ther 17(11):1045\u20131060","journal-title":"Expert Rev Anticancer Ther"},{"issue":"13","key":"4618_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u20131367","journal-title":"JAMA"},{"issue":"1","key":"4618_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","volume":"35","author":"AL Kautio","year":"2008","unstructured":"Kautio AL, Haanpaa M, Saarto T, Kalso E (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 35(1):31\u201339","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"4618_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","volume":"19","author":"DL Barton","year":"2011","unstructured":"Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD, Kugler JW, Hoff KL, Reddy PS, Rowland KM, Riepl M, Christensen B, Loprinzi CL (Jun 2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19(6):833\u2013841","journal-title":"Support Care Cancer"},{"issue":"7","key":"4618_CR7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00520-014-2158-7","volume":"22","author":"JS Gewandter","year":"2014","unstructured":"Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR (2014) A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 22(7):1807\u20131814","journal-title":"Support Care Cancer"},{"issue":"4","key":"4618_CR8","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2011.01.003","volume":"41","author":"R Liebregts","year":"2011","unstructured":"Liebregts R, Kopsky DJ, Hesselink JM (2011) Topical amitriptyline in post-traumatic neuropathic pain. J Pain Symptom Manag 41(4):e6\u2013e7","journal-title":"J Pain Symptom Manag"},{"key":"4618_CR9","doi-asserted-by":"publisher","first-page":"319750","DOI":"10.1155\/2011\/319750","volume":"2011","author":"DJ Kopsky","year":"2011","unstructured":"Kopsky DJ, Keppel Hesselink JM (2011) Multimodal stepped care approach involving topical analgesics for severe intractable neuropathic pain in CRPS type 1: a case report. Case Rep Med 2011:319750","journal-title":"Case Rep Med"},{"key":"4618_CR10","doi-asserted-by":"publisher","first-page":"471835","DOI":"10.1155\/2012\/471835","volume":"2012","author":"DJ Kopsky","year":"2012","unstructured":"Kopsky DJ, Liebregts R, Keppel Hesselink JM (2012) Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case Rep Med 2012:471835","journal-title":"Case Rep Med"},{"issue":"2","key":"4618_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1533-2500.2011.00477.x","volume":"12","author":"DJ Kopsky","year":"2012","unstructured":"Kopsky DJ, Hesselink JM (2012) High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract 12(2):148\u2013153","journal-title":"Pain Pract"},{"key":"4618_CR12","unstructured":"Medicines and Healthcare products Regulatory Agency. Amitriptyline 25mg Tablets BP (PL 15755\/0028) [Internet]. Available from: \n                    http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con2023371.pdf\n                    \n                  . 2006. [Accessed 29th December 2017]"},{"issue":"1\u20132","key":"4618_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3959(98)00195-X","volume":"80","author":"J Sawynok","year":"1999","unstructured":"Sawynok J, Reid AR, Esser MJ (1999) Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain 80(1\u20132):45\u201355","journal-title":"Pain"},{"issue":"3","key":"4618_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0304-3959(98)00261-9","volume":"80","author":"MJ Esser","year":"1999","unstructured":"Esser MJ, Sawynok J (1999) Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. Pain 80(3):643\u2013653","journal-title":"Pain"},{"issue":"3","key":"4618_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/archderm.142.3.283","volume":"142","author":"P Sandroni","year":"2006","unstructured":"Sandroni P, Davis MD (2006) Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? Arch Dermatol 142(3):283\u2013286","journal-title":"Arch Dermatol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4618-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4618-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4618-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:04:58Z","timestamp":1578096298000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4618-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4618"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4618-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"6 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all patients prior to enrolment in the study. The study was approved by the Research Ethics Committee of the H\u00f4pitaux Universitaires Paris-Ouest (HUPO), and by the French Data Protection Authority (Commission Nationale de l\u2019Informatique et des Libert\u00e9s, CNIL).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CG is acknowledged as inventor of a patent application owned by the compagny Algo Therapeutix SAS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have full control of all primary data and agree to allow the journal to review their data if requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}